SCOLR updates

Executive Summary

UPM Pharmaceuticals has agreed to manufacture SCOLR Pharma's controlled delivery technology (CDT) 24-hour OTC pseudoephedrine, SCOLR announces June 6. The Bellevue, Wash.-based firm says it plans to use the UPM-produced PSE tablets in studies to support an NDA, to be submitted to FDA in 2006. UPM also will produce several of SCOLR's other products currently in development, including CDT 12-hour ibuprofen, 12-hour pseudoephedrine and a CDT-based osteoporosis drug raloxifene (Eli Lilly's Evista). Clinical testing has already been initiated for the 12-hour ibuprofen, the company reports...